Research ArticleOpen AccessGoogle Scholar indexed
A New Era in the Adjuvant Treatment of Pancreatic Adenocarcinoma
Oncologia Médica, IPO Porto, Porto, Portugal
Oncologia Médica, IPO Porto, Porto, Portugal
Oncologia Médica, Centro Hospitalar Lisboa Ocidental (CHLO), Lisboa, Portugal
Oncologia Médica, Unidade Local de Saúde de Matosinhos, Hospital Pedro Hispano, Matosinhos, Portugal
- 1 Oncologia Médica, IPO Porto, Porto, Portugal
- 2 Oncologia Médica, IPO Porto, Porto, Portugal
- 3 Oncologia Médica, Centro Hospitalar Lisboa Ocidental (CHLO), Lisboa, Portugal
- 4 Oncologia Médica, Unidade Local de Saúde de Matosinhos, Hospital Pedro Hispano, Matosinhos, Portugal
Journal of Cancer Therapy·Volume 10 (2019)·Pages 915–919·Published 2 December 2019·DOI10.4236/jct.2019.1012078
Copy link · social · email
Abstract
Pancreatic adenocarcinoma is currently a major public health problem, being the 7th cause of death worldwide. Incidence is increasing and unfortunately nowadays the incidence is almost overlapping to mortality. The cornerstone of curative treatment is still surgery, but adjuvant treatment is critical to decreasing the risk of recurrence.
KeywordsPancreatic AdenocarcinomaAdjuvant ChemotherapyPositive Clinical Trials
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
- Riall, T.S. and Lillemoe, K.D. (2007) Underutilization of Surgical Resection in Patients with Localized Pancreatic Cancer. Annals of Surgery, 246, 181-182. https://doi.org/10.1097/SLA.0b013e31811eaa2c
- Hernandez, J.M. (2010) The Natural History of Resected Pancreatic Cancer without Adjuvant Chemotherapy. The American Journal of Surgery, 76, 480-485.
- Rawlaa, P., Sunkarab, T. and Gaduputi, V. (2019) Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World Journal of Oncology, 10, 10-27. https://doi.org/10.14740/wjon1166
- SEER Database. https://seer.cancer.gov/statfacts/html/pancreas.html
- NCCN Guidelines Version 1.2020. Pancreatic Adenocarcinoma: Postoperative-Adjuvant Therapy, 41 p.
- Oettle, H., et al. (2013) Adjuvant Chemotherapy with Gemcitabine and Long-term Outcomes among Patients with Resected Pancreatic Cancer. The CONKO-001 Randomized Trial JAMA, 310, 1473-1481. https://doi.org/10.1001/jama.2013.279201
- Oettle, H., et al. (2007) Adjuvant Chemotherapy with Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial. JAMA, 297, 267-277. https://doi.org/10.1001/jama.297.3.267
- Neoptolemos, J.P., et al. (2010) Adjuvant Chemotherapy with Fluorouracil plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection: A Randomized Controlled Trial. JAMA, 304, 1073-1481. https://doi.org/10.1001/jama.2010.1275
- Uesaka, K., et al. (2016) Adjuvant Chemotherapy of S-1 versus Gemcitabine for Resected Pancreatic Cancer: A Phase 3, Open-Label, Randomized, Non-Inferiority Trial (JASPAC 01). Lancet, 388, 248-257. https://doi.org/10.1016/S0140-6736(16)30583-9
- Neoptolemos, J.P, et al. (2017) Comparison of Adjuvant Gemcitabine and Capecitabine with Gemcitabine Monotherapy in Patients with Resected Pancreatic Cancer (ESPAC-4): A Multicentre, Open-Label, Randomised, Phase 3 Trial. Lancet, 389, 1011-1024. https://doi.org/10.1016/S0140-6736(16)32409-6
- Conroy, T., et al. (2018) FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. The New England Journal of Medicine, 379, 2395-2406. https://doi.org/10.1056/NEJMoa1809775